CL2015001085A1 - Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. - Google Patents

Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.

Info

Publication number
CL2015001085A1
CL2015001085A1 CL2015001085A CL2015001085A CL2015001085A1 CL 2015001085 A1 CL2015001085 A1 CL 2015001085A1 CL 2015001085 A CL2015001085 A CL 2015001085A CL 2015001085 A CL2015001085 A CL 2015001085A CL 2015001085 A1 CL2015001085 A1 CL 2015001085A1
Authority
CL
Chile
Prior art keywords
formulation
oprozomib
preparation
pharmaceutically acceptable
treat cancer
Prior art date
Application number
CL2015001085A
Other languages
English (en)
Inventor
Mouhannad Jumaa
Tony Muchamuel
Naveen Bejugam
Hansen Wong
Christopher J Kirk
Rahul Vishram Manek
Sanjeev Sharma
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CL2015001085A1 publication Critical patent/CL2015001085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2015001085A 2012-10-24 2015-04-24 Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. CL2015001085A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717975P 2012-10-24 2012-10-24
US201261721244P 2012-11-01 2012-11-01
US201361793087P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015001085A1 true CL2015001085A1 (es) 2015-08-28

Family

ID=50485877

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001085A CL2015001085A1 (es) 2012-10-24 2015-04-24 Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.

Country Status (24)

Country Link
US (2) US9295708B2 (es)
EP (1) EP2912025A4 (es)
JP (1) JP6505604B2 (es)
KR (1) KR20150070406A (es)
CN (1) CN104968650A (es)
AP (1) AP3681A (es)
AR (1) AR093126A1 (es)
AU (1) AU2013334258A1 (es)
BR (1) BR112015008572A2 (es)
CA (1) CA2888039A1 (es)
CL (1) CL2015001085A1 (es)
CR (1) CR20150266A (es)
EA (1) EA201590797A1 (es)
HK (2) HK1208222A1 (es)
IL (1) IL238244A0 (es)
IN (1) IN2015DN03921A (es)
MX (1) MX2015005069A (es)
PE (1) PE20151051A1 (es)
PH (1) PH12015500823A1 (es)
SG (1) SG11201502849XA (es)
TN (1) TN2015000135A1 (es)
TW (1) TW201422255A (es)
UY (1) UY35091A (es)
WO (1) WO2014066681A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
EP3310344A1 (en) 2015-06-19 2018-04-25 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
AR108919A1 (es) 2016-06-29 2018-10-10 Kezar Life Sciences Proceso de preparación del inhibidor de inmunoproteasoma de péptido epoxicetona, y sus precursores
US20180078532A1 (en) * 2016-09-21 2018-03-22 Amgen Inc. Immediate release formulations for oprozomib
US20180161279A1 (en) * 2016-12-14 2018-06-14 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
CN110357940A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 奥普佐米合成工艺研究
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
ATE369330T1 (de) * 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
DK2623113T3 (en) * 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
JP5124286B2 (ja) * 2006-01-10 2013-01-23 キッセイ薬品工業株式会社 徐放性製剤およびその製造方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
DK2207791T4 (da) * 2007-10-04 2019-10-07 Onyx Therapeutics Inc Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑

Also Published As

Publication number Publication date
EP2912025A4 (en) 2016-06-08
US20160213610A1 (en) 2016-07-28
CA2888039A1 (en) 2014-05-01
IL238244A0 (en) 2015-06-30
HK1208222A1 (en) 2016-02-26
TW201422255A (zh) 2014-06-16
KR20150070406A (ko) 2015-06-24
WO2014066681A1 (en) 2014-05-01
US9295708B2 (en) 2016-03-29
TN2015000135A1 (en) 2016-10-03
AP2015008387A0 (en) 2015-04-30
MX2015005069A (es) 2015-07-17
AR093126A1 (es) 2015-05-20
EP2912025A1 (en) 2015-09-02
AU2013334258A1 (en) 2015-04-30
JP6505604B2 (ja) 2019-04-24
SG11201502849XA (en) 2015-05-28
PH12015500823A1 (en) 2015-06-22
AP3681A (en) 2016-04-19
UY35091A (es) 2014-05-30
JP2015535255A (ja) 2015-12-10
CR20150266A (es) 2015-08-14
HK1215709A1 (zh) 2016-09-09
EA201590797A1 (ru) 2016-02-29
IN2015DN03921A (es) 2015-10-02
US20140113855A1 (en) 2014-04-24
PE20151051A1 (es) 2015-08-03
CN104968650A (zh) 2015-10-07
BR112015008572A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
HK1252481A1 (zh) 疏水性治療劑的製劑、其製備方法及應用
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
IL240786A0 (en) Preparations, formulations and methods for treating eye diseases
EP2988781A4 (en) Compositions and methods for the therapy and diagnosis of influenza
EP2882362A4 (en) SYSTEMS, DEVICES AND METHODS OF ABLATION FOR TREATING TISSUE
BR112014009634A2 (pt) preparação e agente terapêutico
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
BR112015000437A2 (pt) imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
EP2914326A4 (en) CHEMICAL ABLATION FORMULATIONS AND METHOD FOR THE TREATMENT OF VARIOUS DISEASES
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
CL2014003165A1 (es) Proceso mejorado para la preparación de treprostinil y derivados del mismo.
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
EP3122754A4 (en) Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease
BR112015000527A2 (pt) agente reológico, métodos de preparação e usos dos mesmos.
BR112015006937A2 (pt) formulações espumantes para cuidar da pele.
EP3061452A4 (en) Use of icaritin in preparing medicament for preventing or treating hematocytopenia
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112015005789A2 (pt) Formulações que compreende idebenona, n-acetil- s-farnesil-l-cisteína e ergotioneína e usos das mesmas
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.